NCT06896201 · ACTIVE NOT RECRUITING
Comfortage - AD Prevention Strategies
This Italian study looks at lifestyle-based approaches to Alzheimer's prevention in people with subjective cognitive decline or mild cognitive impairment. It combines physical activity, nutrition, and digital tools with memory testing, blood biomarkers, and brain connectivity analysis. It is not a drug trial. The phase is not applicable, meaning it is not testing a medicine. Details are limited so far.
You may qualify if
- subjective cognitive decline, defined as self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event; normal performance on standardised cognitive tests adjusted for age, sex, and education; decline cannot be explained by psychiatric or other neurologic disease, medical disorder, medication, or substance use; no functional impact on daily life activities
- mild cognitive decline, defined as persistent decline in cognitive performance (in comparison with a previous status) reported by the subject or by an informed caregiver; or observed by change on longitudinal cognitive testing; cognitive performance below expected range for that individual based on cognitive test performance (adjusted for age, sex, and education); performs daily life activities independently (but cognitive difficulty may result in detectable but minimal functional impact on the more complex activities of daily life, either self-reported or corroborated by a study partner); Clinical Dementia Rating Scale = 0.5
- Ability to sign and understand the informed consent form
You're excluded if
- Age under 50 or over 85 years
- Non-native Italian speakers
- Non degenerative and secondary forms of dementia
- Previous or current participation in clinical trials with anti-amyloid agents
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-09-03